MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Johnson and Johnson

Закрыт

СекторЗдравоохранение

160.12 3.04

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

155.34

Макс.

160.62

Ключевые показатели

By Trading Economics

Доход

3.4B

Продажи

20M

23B

P/E

Средняя по отрасли

28.643

63.778

Прибыль на акцию

2.04

Дивидендная доходность

2.99

Рентабельность продаж

15.235

Сотрудники

138,100

EBITDA

652M

5.9B

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+8.41% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

2.99%

2.39%

Следующий отчет о доходах

15 апр. 2025 г.

Следующая эксдивидендная дата

19 мая 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

32B

400B

Предыдущая цена открытия

157.08

Предыдущая цена закрытия

160.12

Новостные настроения

By Acuity

62%

38%

339 / 386 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Weak Bearish Evidence

Johnson and Johnson График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

10 мар. 2025 г., 15:16 UTC

Главные движущие силы рынка

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

10 мар. 2025 г., 13:59 UTC

Главные движущие силы рынка

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

2 апр. 2025 г., 12:49 UTC

Приобретения, слияния, поглощения

Johnson & Johnson Expects 2026 Earnings Dilution to Be Reduced to About 21c/Shr

2 апр. 2025 г., 12:49 UTC

Приобретения, слияния, поглощения

Johnson & Johnson Expects Deal to Dilute Adj EPS by About 25c in 2025 >JNJ

2 апр. 2025 г., 12:48 UTC

Приобретения, слияния, поглощения

J&J: Deal Expected to Accelerate 2025 Sales Growth by About 0.8% With About $700M in Incremental Sales >JNJ

2 апр. 2025 г., 12:45 UTC

Приобретения, слияния, поглощения

J&J: Addition of CAPLYTA Strengthens Lineup of Therapies With $5 Billion+ Potential in Peak Yr Sales >JNJ

2 апр. 2025 г., 12:44 UTC

Приобретения, слияния, поглощения

Johnson & Johnson: sNDA Submitted to FDA for CAPLYTA as Adjunctive Treatment for Major Depressive Disorder >JNJ

2 апр. 2025 г., 12:44 UTC

Приобретения, слияния, поглощения

Johnson & Johnson Closes Landmark Intra-Cellular Therapies Acquisition to Solidify Neuroscience Leadership

1 апр. 2025 г., 20:07 UTC

Приобретения, слияния, поглощения

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

1 апр. 2025 г., 16:09 UTC

Отчет

These Stocks Are Moving the Most Today: Tesla, Johnson & Johnson, Southwest, Delta, MicroStrategy, PVH, Newsmax, and More -- Barrons.com

1 апр. 2025 г., 13:51 UTC

Отчет

These Stocks Are Moving the Most Today: Tesla, Johnson & Johnson, PVH, Southwest, Newsmax, and More -- Barrons.com

1 апр. 2025 г., 12:15 UTC

Главные новости

Johnson & Johnson Stock Falls After Latest Talc Resolution Rejected -- Barrons.com

1 апр. 2025 г., 11:37 UTC

Обсуждения рынка

Johnson & Johnson To Reverse $7 Billion of Talc Reserve -- Market Talk

1 апр. 2025 г., 10:36 UTC

Отчет

These Stocks Are Moving the Most Today: Tesla, XPeng, PVH, Progress Software, J&J, Newsmax, Southwest, and More -- Barrons.com

1 апр. 2025 г., 01:04 UTC

Главные новости

Johnson & Johnson's Third Bankruptcy Case for Talc Lawsuits Thrown Out -- WSJ

21 мар. 2025 г., 23:02 UTC

Приобретения, слияния, поглощения

Ranking the S&P 500s Most Defensive Stocks -- Barrons.com

21 мар. 2025 г., 13:35 UTC

Отчет
Популярные акции

Stocks to Watch Friday: J&J, Nike, FedEx, Micron -- WSJ

14 мар. 2025 г., 09:30 UTC

Главные новости

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

7 мар. 2025 г., 01:00 UTC

Главные новости

Finance Executives Seek Stability Amid Erratic Tariff Shifts -- WSJ

18 февр. 2025 г., 22:22 UTC

Главные новости

Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan -- Update

14 февр. 2025 г., 13:00 UTC

Главные новости

J&J's High Hopes for Heart-Rhythm Device Grounded by Safety Concerns -- WSJ

24 янв. 2025 г., 07:00 UTC

Главные новости

Disasters Spawn New Businesses. The California Wildfires Will Do the Same. -- Barrons.com

22 янв. 2025 г., 21:39 UTC

Отчет

These Stocks Moved the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 янв. 2025 г., 19:41 UTC

Отчет

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 янв. 2025 г., 17:38 UTC

Обсуждения рынка
Отчет

J&J's Forex Headwind in Outlook Surprised Investors -- Market Talk

22 янв. 2025 г., 16:48 UTC

Отчет

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 янв. 2025 г., 14:51 UTC

Отчет

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Ford, and More -- Barrons.com

22 янв. 2025 г., 14:09 UTC

Главные новости
Отчет

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22 янв. 2025 г., 13:04 UTC

Отчет

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Travelers, and More -- Barrons.com

22 янв. 2025 г., 12:47 UTC

Отчет

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Agilysys, and More -- Barrons.com

Сравнение c конкурентами

Изменение цены

Johnson and Johnson Прогноз

Целевая цена

By TipRanks

8.41% рост

Прогноз на 12 месяцев

Средняя 168.42 USD  8.41%

Максимум 185 USD

Минимум 152 USD

Основано на мнении 14 аналитиков Wall Street, спрогнозировавших целевые цены для Johnson and Johnson  на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

14 ratings

6

Покупка

8

Удержание

0

Продажа

Техническая оценка

By Trading Central

153.13 / 164.36Поддержка и Сопротивление

Краткосрочная

Weak Bearish Evidence

Среднесрочная

Bullish Evidence

Долгосрочная

Weak Bearish Evidence

Настроения

By Acuity

339 / 386Рейтинг в Здравоохранение

Новостные настроения

Свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.